Loading ...
Sorry, an error occurred while loading the content.

889PR: O6 Benzyl Guanine /Antinuclear autoantibodies (ANAs)

Expand Messages
    Sep 14 11:23 AM
    • 0 Attachment
      Two press releases from today, one on O6 Benzyl Guanine and the other
      on ANAs which could be beneficial to treating lymphoma.

      Monday September 14, 8:08 am Eastern Time

      Company Press Release

      SOURCE: Pacific Pharmaceuticals, Inc.

      Pacific Pharmaceuticals, Inc.
      Announces National Cancer Institute - Sponsored
      Trial At Duke University Medical Center

      O6 Benzyl Guanine Chemosensitizer To Be Studied In Brain

      SAN DIEGO, Sept. 14 /PRNewswire/ -- Pacific Pharmaceuticals, Inc.
      (Amex: PHA - news) today announced the initiation of a Phase I human
      clinical trial of its O6 Benzyl Guanine (BG) chemosensitizing agent for the
      treatment of brain tumors at the Duke University Medical Center under the
      direction of Henry S. Friedman, M.D., Professor of Pediatrics and Associate
      Professor of Surgery and Medicine. This study is one of several clinical trials
      sponsored by the National Cancer Institute (NCI) to be conducted under the
      Cooperative Research and Development Agreement (CRADA)
      recently signed with the NCI. Six patients have been recruited as enrollment
      continues for the study designed to determine the optimal dose of BCNU, a
      commonly used alkylating agent used to treat brain cancer, in combination
      with BG in patients with recurrent, persistent or progressive cerebral
      anaplastic glioma.

      O6 Benzyl Guanine (BG) is a chemosensitizer which may break down tumor
      resistance to a significant class of commonly used chemotherapeutic agents
      known as O6 alkylators. BG may also enhance the activity of the O6
      alkylators, and may enable the drugs to work more effectively at a lower
      dose. ``Brain cancer is a very debilitating disease for which there are few
      treatment alternatives and almost no cures,'' commented Dr. Friedman. ``We
      are very anxious to assess the combination therapy utilizing BG with BCNU
      in these brain cancer patients, as it may provide a valuable improvement in
      our ability to induce tumor regression and manage the disease more

      Pre-clinical studies sponsored by the NCI, conducted by Pugh Scholar Dr.
      Anthony E. Pegg, Professor of Cellular and Molecular Physiology at
      Pennsylvania State University, and his colleagues indicate that BG
      inactivates tumor AGT, a tumor DNA repair protein (O6 alkylguanine-DNA
      alkyltransferase), which interferes with the effectiveness of the alkylating
      agents and ultimately enables tumor resistance to the drugs. Human clinical
      data show that a correlation exists between low levels of the
      tumor repair protein AGT, and enhanced responsiveness to treatment.
      Conversely, patients with high levels of tumor AGT protein had a lower
      response to similar chemotherapy. Pre-clinical animal data demonstrate that
      treatment with BG increased the anti-tumor activity of the alkylating agents
      resulting in prolonged survival.

      The effective dose for BG that significantly inactivates the tumor DNA repair
      protein AGT has been determined in NCI-sponsored Phase I studies
      performed at the Duke University Medical Center, the University of Chicago
      and Case Western Reserve University. Phase I clinical studies at these
      institutions are also ongoing with some nearing completion to determine the
      optimum dose of the O6 alkylating agent BCNU that can be combined with
      the previously determined effective dose of BG. The Company believes that
      BG has the potential to expand the indications for O6 alkylating agents used
      primarily to treat brain cancer, melanoma and lymphoma, to other cancers
      previously considered to be unresponsive to that class of cancer drugs.

      Pacific Pharmaceuticals, together with its majority owned subsidiary BG
      Development Corporation, has two of three cancer therapies in the human
      clinical phase of development under US Food and Drug Administration
      (FDA) Investigational New Drug Applications (INDs). These therapies
      include O6 Benzyl Guanine (under an NCI sponsored IND), and a boronated
      porphyrin (BOPP) for use in photodynamic therapy (PDT). The Company's
      cancer immunotherapy is in pre-clinical development for the
      treatment of metastatic cancer.

      This news release contains forward-looking statements. The actual results
      could vary from those expected due to a variety of risks set forth from time to
      time in the Company's filings with the Securities and Exchange Commission,
      including the Company's Form 10-K for the year ended March 31, 1998. The
      Company undertakes no obligation to publicly release the results of any of
      these forward looking statements which may be made to reflect events or
      circumstances after the date hereof or to reflect the occurrence of
      unanticipated events.

      SOURCE: Pacific Pharmaceuticals, Inc.


      More Quotes and News:
      Pacific Pharmaceuticals Inc (AMEX:PHA - news)
      Related News Categories: biotech, medical/pharmaceutical

      Monday September 14, 10:26 am Eastern Time

      Company Press Release

      SOURCE: Procyon Biopharma Inc.

      Procyon BioPharma
      Announces Issuance of a United States Patent for
      the Use of Antinuclear Autoantibodies in the
      Treatment of Cancer

      LONDON, Ont., Sept. 14 /CNW-PRN/ - Procyon BioPharma Inc.
      (ASE:PBP) announced today that United States Patent No. 5,780,033,
      broadly covering the production and use of the Company's non-pathogenic
      antinuclear autoantibodies (ANAs) for the treatment of cancer, has issued.

      The patent is anticipated to provide proprietary protection to ANA-based
      cancer therapeutics derived from a specific set of naturally occurring
      autoantibodies discovered in the blood of healthy aged animals by Dr.
      Vladimir Torchilin and his colleagues while at the Massachusetts General
      Hospital. In pre-clinical tissue culture studies published in the Journals
      Oncology Research and Immunology Letters, these antibodies have been
      shown to bind selectively to a variety of human cancer cell lines
      including prostate cancer, breast cancer, lymphoma and leukemia. In
      addition, these ANAs have been shown to reduce tumor development or
      improve survival in lymphoma and melanoma mouse models.

      The ANA technology is based on the discovery of naturally occurring
      antibodies that bind to nucleosomes, small particles of nuclear material on
      the surface of cancer cells. Cancer cells may attach nucleosomes to their
      surface to assist them in evading the immune system, as nucleosomes have
      the ability to suppress the immune system's response to abnormal cells.
      ANAs may enhance the body's natural immunological cancer fighting

      ``The issuance of this patent confirms the inventiveness and novelty of Dr.
      Torchilin's important discovery, and the patent is anticipated to provide
      proprietary protection to our unique antibodies that target many of the major
      types of cancer. The technology offers the Company the opportunity to
      develop a broad platform of potent anti-cancer therapeutics using a single
      class of therapeutic antibodies.'' said Dr. Chandra Panchal,
      President and Chief Executive Officer of Procyon BioPharma Inc.

      Procyon BioPharma is a biopharmaceutical company engaged in the
      discovery and development of innovative products for the treatment and
      diagnosis of cancer. The Company is advancing a broad pipeline of
      products based on its proprietary Antinuclear Auto-Antibody (ANA) and
      Prostate Secretory Protein (PSP(94)) technologies. Procyon BioPharma has
      two products in late-stage development, COLOPATH(TM), a rapid,
      point-of-care screening test for colorectal cancer, and
      FIBROSTAT(TM), a topical therapeutic cream designed to prevent
      hypertrophic scarring following surgery or serious burns. The Company is
      headquartered in London, Ontario with research facilities in London, Ontario
      and Boston, Massachusetts.

      This news release may contain ``forward-looking statements'' based upon
      current expectations but involving known and unknown risks and
      uncertainties. Actual results or achievements of the Company may be
      materially different from those expressed or implied. The Company's current
      plans and objectives are based upon assumptions involving judgments with
      respect to factors including technology development,
      economic, competitive and market conditions and future business decisions.
      These factors are difficult or impossible to predict accurately, may change
      and many are beyond the control of the Company. Therefore, investors are
      cautioned that there can be no assurance that the forward-looking
      statements will prove to be accurate.

      ``The Alberta Stock Exchange has neither approved or disapproved the
      information contained herein.''

      SOURCE: Procyon Biopharma Inc.